GLG News by Byetta Prescribers for Diabetes (US)

1.Hypertriglyceridemia causes pancreatitis 2.Most PCP, endocrinologists, and cardiologists are not effectively treating high triglycerides, and may make it worse by recommending a low fat = high carb diet 3.Accord data with 75% reduction in death, and patients desparate for wt loss will continue to...

Most hospitals are financially built on their heart programs. The "agressive" medical arm is conservative by our standards yet as good as stents at far less cost. If this was truly pursued by large companies with TPA insurance plans, their overall cost would drop with large savings in healthcare costs....

The ACCORD trial results were no suprise to our diabetes practice. We have been heavy users of Byetta since launch in 2005, and have seen the same results in our population of > 2000 diabetics with over 700 on Byetta. Since the Simpson et al study in the Canadian Journal of Medicine (CMAJ 2006;174(2):169-74)...

The recent finding that Byetta therapy decreased mortality in the ACCORD study needs to be replicated in studies designed to address that point.  Even if it is replicated and statistically significant, it probably will not be true for the widely anticipated once weekly extended formulation...

Therapeutic effects of drugs are seen essentially in all treated patients.  Adverse outcomes are infrequent.  The July 1-2 FDA diabetes panel recommendation that sturdy systems for determining outcome should be required for all new diabetes treatments may lead to a >100-fold increase in...

More than 50% of patients have the 3 ccomponents to qualify for diagnosis of Metabolic Syndrome.Twwo of the components,Diabetes and Obesity are present in 20-25% of them and are difficult to control.Exenatide seems to provide that benefit.

As exciting as the DURATION I study results have been, Roche's GLP-1 agonist is also looking good in earlier phase trials, and there are MANY competitors in this GLP-1 realm, as well as the gliptins (oral, with similar efficacy on glucose and A1c but without the dramatic weight loss), chomping at the...

This compound may have additiional benefit in type 2 diabetic patients, especially those with the cardiometabolic syndrome. 

I am a heavy user of ARB's and Tekturna.  This article does not really show anything of significance.  Most practicing physicians have seen much better results and much better tolerability with ARB's than diuretics. I do not think this is going to change prescribing habits of anyone. ...

 Study will be ridiculed.   1) Comparator drug is not appropriate. 2) Not an outcomes study. 3) Time frame too short to be clinically significant. 4) Drug too expensive for first line use. 5) Long term safety not established.